<DOC>
	<DOCNO>NCT02237053</DOCNO>
	<brief_summary>The purpose study collect data help researcher well understand effect glucagon amount calorie burn .</brief_summary>
	<brief_title>Effects Glucagon Administration Energy Expenditure</brief_title>
	<detailed_description>1 . To compare effect prolonged hyperglucagonemia acute hyperglucagonemia energy expenditure healthy subject use room indirect calorimetry set octreotide-mediated prevention plasma insulin excursion . 2 . To compare effect prolong hyperglucagonemia acute hyperglucagonemia EGP healthy subject set octreotide-mediated prevention plasma insulin excursion . 3 . To determine effect prolong hyperglucagonemia acute hyperglucagonemia rate substrate oxidation , fibroblast growth factor21 metabolites interest .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Subject male age 18 50 year . Subject body mass index ( BMI ) less equal 26 kg/m2 . BMI = weight ( kg ) /height ( ) body weight great equal 50 kg prestudy ( screen ) visit Subject weight stable last 3 month ( plus minus 3 kg ) Subject judge nondiabetic good health basis medical history , physical examination , electrocardiogram , routine laboratory data . Subject understands procedure agree participate study program give write informed consent , willing comply trial restriction . Subject willing avoid alcohol consumption 48 hour prior period . Subject willing avoid strenuous physical activity ( i.e. , strenuous unaccustomed weight lifting , run , bicycling , etc . ) begin 72 hour prior first drug administration period duration study . Subject willing avoid consumption caffeine caffeinated beverage 24 hour prior drug administration period . Subject willing consume 2 caffeinated beverage per day part study . mentally legally incapacitate , significant emotional problem time pretrial ( screen ) visit expect conduct trial history clinically significant psychiatric disorder last 5 year . Subjects situational depression may enrol trial discretion investigator . history clinically significant endocrine ( include type 1 type 2 , steroidinduced diabetes ) , gastrointestinal ( include prior history pancreatitis ) , cardiovascular ( include hypertension , angina , coronary artery disease , valvular disease , heart rate rhythm abnormality ) , hematological , hepatic , immunological , renal , respiratory , genitourinary major neurological ( include stroke chronic seizure ) abnormality diseases . Subjects history uncomplicated kidney stone childhood asthma may enrol trial discretion investigator . know history endocrine tumor ( e.g . pheochromocytoma , glucagonoma , insulinoma , etc . ) clinically significant abnormality screen ECG evidence history myocardial ischemia , atrioventricular block , WolfParkinsonWhite syndrome conduction abnormality . Subjects clinically significant ECG abnormality screening may include discretion PI . fast blood glucose ( FPG ) less equal 65 mg/dL great equal 100 mg/dL prestudy screen lab . impaired kidney liver function , evidence screen blood work . irritable bowel disease , recurrent occurrence nausea , vomit , diarrhea , constipation abdominal pain . history illness , opinion study investigator , might confound result study pose additional risk subject participation study . estimate creatinine clearance â‰¤80 mL/min base CockcroftGault equation history neoplastic disease history significant multiple and/or severe allergy ( e.g . food , drug , latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food ; allergy/intolerability insulin , glucagon , octreotide . positive hepatitis B surface antigen , hepatitis C antibody , HIV major surgery within 3 month , donate lose 1 unit blood ( approximately 500 mL ) within 4 week prior pretrial ( screen ) visit . participate another investigational trial within 4 week prior pretrial ( screen ) visit . The 4 week window derive date last trial medication / blood collection previous trial and/or adverse event relate trial drug pretrial/screening visit current trial . consumes great 2 glass alcoholic beverage ( 1 glass approximately equivalent : beer [ 354 mL/12 ounce ] , wine [ 118 mL/4 ounce ] , distilled spirit [ 29.5 mL/1 ounce ] ) per day . Patients consume 4 glass alcoholic beverage per day may enrol discretion investigator . consumes excessive amount , define great 4 serving ( 1 serve approximately equivalent 120 mg caffeine ) coffee , tea , cola , energydrinks , caffeinated beverage per day . currently regular user ( include `` recreational use '' ) illicit drug history drug ( include alcohol ) abuse within approximately 3 month screen visit . unwilling unable adhere dietary need study , consume standardize meal study , and/or carbohydrate restrict diet ( i.e. , diet &lt; 100 gram per day carbohydrate ) . concern investigator regard safe participation subject trial reason ; investigator considers subject inappropriate participation trial . history claustrophobia claustrophobic . ever organ transplant . smoker use nicotinecontaining product ( least 6 month prior drug administration ) ; plan begin smoke use nicotinecontaining product conduct study . poor intravenous access . used medication know influence glucose , fat , energy metabolism within last 3 month ( growth hormone , steroid , etc . ) blood pressure screen visit less equal 100/50 mm Hg great equal 160/100 mm Hg .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Energy expenditure</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Octreotide</keyword>
	<keyword>Weight loss</keyword>
</DOC>